Assessing Prolongation of the Corrected QT Interval with Bedaquiline and Delamanid Coadministration to Predict the Cardiac Safety of Simplified Dosing Regimens-Reference-Cited by-同舟云学术

Assessing Prolongation of the Corrected QT Interval with Bedaquiline and Delamanid Coadministration to Predict the Cardiac Safety of Simplified Dosing Regimens

Published:2022-07-13 Issue:4 Volume:112 Page:873-881
ISSN:0009-9236
Container-title:Clinical Pharmacology & Therapeutics
language:en
Short-container-title:Clin Pharma and Therapeutics

Author:

Tanneau Lénaïg¹^ORCID,Karlsson Mats O.¹^ORCID,Rosenkranz Susan L.²,Cramer Yoninah S.²,Shenje Justin³,Upton Caryn M.⁴,Morganroth Joel⁵,Diacon Andreas H.⁴,Maartens Gary⁶,Dooley Kelly E.⁷^ORCID,Svensson Elin M.¹⁸^ORCID

Affiliation:

1. Department of Pharmacy Uppsala University Uppsala Sweden

2. Frontier Science Foundation Brookline Massachusetts USA

3. South African Tuberculosis Vaccine Initiative, University of Cape Town Cape Town South Africa

4. TASK Applied Science Cape Town South Africa

5. Clario, Inc. Philadelphia Pennsylvania USA

6. Division of Clinical Pharmacology, Department of Medicine University of Cape Town Cape Town South Africa

7. Center for Tuberculosis Research Johns Hopkins University School of Medicine Baltimore Maryland USA

8. Department of Pharmacy, Radboud Institute for Health Sciences Radboud University Medical Center Nijmegen The Netherlands

Funder

National Institutes of Health

ACT Government

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cpt.2685

Reference31 articles.

1. World Health Organization.Global tuberculosis report 2020 (2020).

2. Infographic: Drug‐resistant TB: How many pills does it take? Médecins Sans Frontières Access Campaign.

3. World Health Organization.Consolidated Guidelines on Tuberculosis Module 4: Treatment – Drug‐Resistant Tuberculosis Treatment. (2020).

4. Culture Conversion in Patients Treated with Bedaquiline and/or Delamanid. A Prospective Multicountry Study

5. Compassionate use of delamanid in combination with bedaquiline for the treatment of multidrug-resistant tuberculosis

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Multidrug-resistant tuberculosis;Nature Reviews Disease Primers;2024-03-24

2. Second-line antituberculosis drug exposure thresholds predictive of adverse events in multidrug-resistant tuberculosis treatment;International Journal of Infectious Diseases;2024-03

3. In silico drug design strategies for discovering novel tuberculosis therapeutics;Expert Opinion on Drug Discovery;2024-02-19

4. Model‐based dose optimization framework for bedaquiline, pretomanid and linezolid for the treatment of drug‐resistant tuberculosis;British Journal of Clinical Pharmacology;2023-10-26

5. Coadministration of bedaquiline and pyrifazimine reduce exposure to toxic metabolite N-desmethyl bedaquiline;Frontiers in Pharmacology;2023-10-04